AgingResearch.NewsJoin free

Taisho Pharmaceutical

CompanyJapan

Taisho Pharmaceutical develops 2 assets, the furthest approved (minoxidil in female pattern hair loss). Mostly small molecule acting on KCNJ8; based in Japan.

2
Assets
Furthest stage
Approved
1
Trial
1
Signal

Pipeline

2

  • minoxidil

    Opens potassium channels and promotes hair follicle growth.

    Approved, Small molecule, KCNJ8, female pattern hair loss, hair loss

  • TS-172

    Non-absorbed phosphate binder that decreases phosphate absorption

    Phase 3, Small molecule, hyperphosphatemia patients on hemodialysis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials2
  • Signals3
  • Similar companies3

Papers

Intelligence